Is there a future for tigecycline?

[1]  H. Dupont,et al.  Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting , 2014, Intensive Care Medicine.

[2]  Hsin-Yun Sun,et al.  Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis , 2014, BMC Infectious Diseases.

[3]  H. Maltezou,et al.  Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[4]  M. Bassetti,et al.  Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies. , 2013, The Journal of antimicrobial chemotherapy.

[5]  R. D. Meyer,et al.  All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials. , 2013, International journal of antimicrobial agents.

[6]  Y.-T. Lee,et al.  Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections , 2013, European Journal of Clinical Microbiology & Infectious Diseases.

[7]  P. G. Choe,et al.  Tigecycline in carbapenem-resistant Acinetobacter baumannii bacteraemia: Susceptibility and clinical outcome , 2013, Scandinavian journal of infectious diseases.

[8]  M. Antonelli,et al.  High-dose tigecycline use in severe infections , 2013, Critical Care.

[9]  J. Ramirez,et al.  Randomized Phase 2 Trial To Evaluate the Clinical Efficacy of Two High-Dosage Tigecycline Regimens versus Imipenem-Cilastatin for Treatment of Hospital-Acquired Pneumonia , 2013, Antimicrobial Agents and Chemotherapy.

[10]  K. Kaye,et al.  Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections. , 2012, American journal of infection control.

[11]  K. Peck,et al.  Clinical experience of tigecycline treatment in infections caused by extensively drug-resistant Acinetobacter spp. , 2012, Microbial drug resistance.

[12]  M. Bassetti,et al.  Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  M. Tziraki,et al.  Comparative Evaluation of Tigecycline Susceptibility Testing Methods for Expanded-Spectrum Cephalosporin- and Carbapenem-Resistant Gram-Negative Pathogens , 2012, Journal of Clinical Microbiology.

[14]  C. Natanson,et al.  Excess deaths associated with tigecycline after approval based on noninferiority trials. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  M. Falagas,et al.  Effectiveness and safety of tigecycline: focus on use for approved indications. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  P. Nordmann,et al.  Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli. , 2012, International journal of antimicrobial agents.

[17]  K. Ko,et al.  In vitro time-kill studies of antimicrobial agents against blood isolates of imipenem-resistant Acinetobacter baumannii, including colistin- or tigecycline-resistant isolates. , 2012, Journal of medical microbiology.

[18]  H. Leu,et al.  The clinical implication and prognostic predictors of tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii. , 2011, The Journal of infection.

[19]  A. Haidich,et al.  Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. , 2011, The Lancet. Infectious diseases.

[20]  L. Leibovici,et al.  Efficacy and safety of tigecycline: a systematic review and meta-analysis. , 2011, The Journal of antimicrobial chemotherapy.

[21]  R. Guner,et al.  Outcomes in patients infected with carbapenem-resistant Acinetobacter baumannii and treated with tigecycline alone or in combination therapy , 2011, Infection.

[22]  Yee-Chun Chen,et al.  Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU. , 2011, Diagnostic microbiology and infectious disease.

[23]  S. Kuo,et al.  Clinical experience with tigecycline as treatment for serious infections in elderly and critically ill patients. , 2011, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[24]  You-ning Liu,et al.  Systematic Review and Meta-Analysis of the Effectiveness and Safety of Tigecycline for Treatment of Infectious Disease , 2010, Antimicrobial Agents and Chemotherapy.

[25]  Y. Chuang,et al.  Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. , 2010, Diagnostic microbiology and infectious disease.

[26]  E. Alp,et al.  Clinical Experience with Tigecycline in the Treatment of Carbapenem-Resistant Acinetobacter Infections , 2010, Journal of chemotherapy.

[27]  V. Rotimi,et al.  Role of tigecycline in the control of a carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit. , 2009, The Journal of hospital infection.

[28]  C. Nicolaou,et al.  Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. , 2009, The Journal of infection.

[29]  N. Gordon,et al.  A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. , 2009, The Journal of antimicrobial chemotherapy.

[30]  C. Luna,et al.  Late Onset Ventilator-Associated Pneumonia Due to Multidrug-Resistant Acinetobacter spp.: Experience with Tigecycline , 2009, Journal of chemotherapy.

[31]  Arthur J. L. Cooper,et al.  A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. , 2008, The Journal of antimicrobial chemotherapy.

[32]  Jason C. Gallagher,et al.  Tigecycline for the Treatment of Acinetobacter Infections: A Case Series , 2008, The Annals of pharmacotherapy.

[33]  M. Büchler,et al.  Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit. , 2008, The Journal of antimicrobial chemotherapy.

[34]  D. Linkin,et al.  Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  J. Schafer,et al.  Early Experience with Tigecycline for Ventilator‐Associated Pneumonia and Bacteremia Caused by Multidrug‐Resistant Acinetobacter baumannii , 2007, Pharmacotherapy.